Context Therapeutics Inc (CNTX)
2.15
+0.01
(+0.47%)
USD |
NASDAQ |
Jun 25, 16:00
2.15
0.00 (0.00%)
After-Hours: 19:31
Context Therapeutics Enterprise Value: 150.41M for June 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 24, 2024 | 150.41M |
| June 21, 2024 | 151.91M |
| June 20, 2024 | 152.66M |
| June 18, 2024 | 141.41M |
| June 17, 2024 | 135.41M |
| June 14, 2024 | 136.91M |
| June 13, 2024 | 137.66M |
| June 12, 2024 | 139.91M |
| June 11, 2024 | 143.66M |
| June 10, 2024 | 134.66M |
| June 07, 2024 | 118.16M |
| June 06, 2024 | 121.16M |
| June 05, 2024 | 123.41M |
| June 04, 2024 | 125.66M |
| June 03, 2024 | 142.91M |
| May 31, 2024 | 138.41M |
| May 30, 2024 | 139.91M |
| May 29, 2024 | 139.91M |
| May 28, 2024 | 142.91M |
| May 24, 2024 | 139.91M |
| May 23, 2024 | 136.16M |
| May 22, 2024 | 136.16M |
| May 21, 2024 | 142.16M |
| May 20, 2024 | 139.16M |
| May 17, 2024 | 139.91M |
| Date | Value |
|---|---|
| May 16, 2024 | 124.91M |
| May 15, 2024 | 116.66M |
| May 14, 2024 | 118.16M |
| May 13, 2024 | 115.91M |
| May 10, 2024 | 130.16M |
| May 09, 2024 | 127.16M |
| May 08, 2024 | 125.66M |
| May 07, 2024 | 118.91M |
| May 06, 2024 | 123.41M |
| May 03, 2024 | 19.45M |
| May 02, 2024 | 17.85M |
| May 01, 2024 | 11.62M |
| April 30, 2024 | 11.38M |
| April 29, 2024 | 11.78M |
| April 26, 2024 | 12.42M |
| April 25, 2024 | 11.94M |
| April 24, 2024 | 10.67M |
| April 23, 2024 | 12.42M |
| April 22, 2024 | 11.62M |
| April 19, 2024 | 10.99M |
| April 18, 2024 | 12.42M |
| April 17, 2024 | 12.10M |
| April 16, 2024 | 13.22M |
| April 15, 2024 | 13.86M |
| April 12, 2024 | 13.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-29.68M
Minimum
Dec 28 2022
152.66M
Maximum
Jun 20 2024
1.026M
Average
-10.44M
Median
Enterprise Value Benchmarks
| Emergent BioSolutions Inc | 1.182B |
| AbbVie Inc | 361.01B |
| Revance Therapeutics Inc | 420.15M |
| Design Therapeutics Inc | -81.43M |
| NovaBay Pharmaceuticals Inc | 2.982M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.668M |
| Total Expenses (Quarterly) | 3.824M |
| EPS Diluted (Quarterly) | -0.23 |
| Earnings Yield | -61.86% |